Motion Sickness
-
FDA Lifts Partial Hold on Motion Sickness Drug Tradipitant
words.The FDA has lifted the partial clinical hold on Vanda Pharmaceuticals’ tradipitant study, reclassifying the NK‑1 antagonist as an event‑driven therapy for motion sickness and dropping the six‑month canine toxicity requirement. Vanda can now expand dosing and keep its NDA on track for a PDUFA decision by Dec. 30, 2025, potentially delivering the first new pharmacologic motion‑sickness treatment in over 40 years. Analysts estimate a $1.5 billion annual market, and the drug’s favorable safety profile could also enable combination strategies with GLP‑1 agonists.
